Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG®

Surgical Site Infection Clinical Trial

Official title:

A Prospective, Randomized, Double-blind, Placebo-controlled Phase I/IIa Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG® in Bacterial Infection Treatment in Patients With Surgical Wounds

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06319235
• Other study ID #: DUO2022_01
• Secondary ID: 2022-002412-23
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: October 27, 2023
• Est. completion date: December 31, 2025

Study information

• Verified date: March 2024
• Source: MB PHARMA s.r.o.
• Contact: Dana Štveráková, Ph.D.
• Phone: +420 604 912 940
• Email: stverakova[@]mbph.cz
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

DUOFAG® is a phage cocktail containing bacteriophages active against Staphylococcus aureus and Pseudomonas aeruginosa. It is an investigational medicinal product for the treatment of surgical site infections caused by S. aureus and P. aeruginosa.

The primary objective of the study is to demonstrate the safety of DUOFAG® and the clinical and microbiological change within 10 weeks after the start of treatment or until healing.

Description:

The study population will be recruited in two cohorts. The microbiological population of the wound will be evaluated to analyze the effect of the treatment. If the safety profile and treatment effect are going to be satisfactory, the recruitment will proceed with Cohort 2.

In both cohorts, the Investigational Medicinal Product (IMP) or placebo (the randomization ratio will be 1:1) will be applied twice a day for two weeks or until the commencement of healing.

Patients will receive the standard of care during the whole study duration. No concomitant treatment is planned during the treatment period.

The Adverse Events will be recorded on basis of an open interview without soliciting questions, and clinical observation. In case of occurrence of an adverse event (AE) with moderate or severe intensity possibly related to IMP, the treatment will be stopped, and the AE will be followed up until resolution.

Adverse Event descriptions, their severity (mild, moderate, or severe), duration and their perceived relationship to the study medication (probable, possible, unlikely, not related, and not sure) will be recorded.

The mLUMT (modified Leg Ulcer Measurement Tool) total score and individual item scores change since the baseline visit will be recorded.

Time from the start of the study treatment until the bacterial infection eradication - i. e. the swab sample is negative on S. aureus and/or P. aeruginosa will be recorded.

Time from the start of the study treatment until the wound is closed/healed (as assessed by investigator) will be recorded.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 52
• Est. completion date: December 31, 2025
• Est. primary completion date: December 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Patients with surgical wound infection and/or dehiscence

• Wound infected by S. aureus and/or P. aeruginosa according to wound swab.

• Wound in the groin or any other skin fold as per Investigator's discretion.

• Signed Informed Consent Form, approved by the ethical committee and competent authority.

• The age between 18 and 75 years.

• Patients able and willing to comply with study procedures.

• There are no contraindications for planned concomitant medication.

• Persisting symptoms of bacterial infection < 3 weeks since the surgery.

• Women of childbearing potential must take highly effective contraceptive measures since the study start and one month after the treatment administration at a minimum.

Exclusion Criteria:

• History of an organ or bone marrow transplantation.

• Any autoimmune disease.

• Uncompensated diabetes mellitus, confirmed by the concentration of HbA1c >60 mmol/mol (6%).

• Systematic immunosuppressive therapy.

• Malignancy treatment <1 year before the Baseline visit.

• COVID-19 infection <3 months before the Baseline visit, any signs of post-COVID syndrome.

• Pregnancy or planning to become pregnant during the study.

• Breastfeeding.

• Participation in another clinical study.

• Hypersensitivity to the IMP or placebo.

Related Conditions & MeSH terms

• Bacterial Infections
• Communicable Diseases
• Infections
• Pseudomonas Aeruginosa Infection
• Pseudomonas Infections
• Staphylococcal Infections
• Staphylococcus Aureus Infection
• Surgical Site Infection
• Surgical Wound
• Surgical Wound Infection
• Wound Infection

Intervention

Drug:
• IMP
DUOFAG® is a phage cocktail (cutaneous liquid) manufactured by MB PHARMA s.r.o. and it contains bacteriophages active against Staphylococcus aureus and Pseudomonas aeruginosa.
• Placebo
0.9% Sodium Chloride Injection solution was manufactured by B. Braun Melsungen AG. Marketing authorization number assigned from the State Institute for drug control (Czech Republic): 76/847/92-B/C

Locations

Country	Name	City	State
Czechia	St. Anne's University Hospital Brno	Brno	Czech Republic

Sponsors (1)

Lead Sponsor	Collaborator
MB PHARMA s.r.o.

Country where clinical trial is conducted

Czechia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary endpoint - Cohort 1	The endpoint will be the frequency of all (local and systemic) reactions with suspected or confirmed relation to IMP.	10 weeks (the maximum duration)
Primary	Primary endpoint - pooled Cohorts 1 & 2	Time to commencement of healing.	10 weeks (the maximum duration)
Secondary	Safety endpoints (assessed in pooled Cohorts 1 & 2)	The frequency of the following symptoms following the IMP application will be evaluated: local reactions, systemic reactions.	10 weeks (the maximum duration)
Secondary	Microbiological endpoints (assessed in pooled Cohort 1 and Cohort 2)	Change of the microbiological profile of the wound assessed by swab.	2 weeks (the maximum duration)
Secondary	Clinical efficacy endpoints	The mLUMT total score change since Baseline, time since the start of the study treatment until the bacterial infection eradication, time since the start of the study treatment until the granulation process in the wound has started, time since the start of the study treatment until the wound is closed as assessed by Investigator.	10 weeks (the maximum duration)

External Links

•   MB PHARMA website